Cita APA

Falchi, L., Sureda, A., Lugtenburg, P. J., Leppä, S., Vermaat, J. S. P., Nijland, M., . . . Belada, D. (2025). Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Citación estilo Chicago

Falchi, Lorenzo, et al. Fixed-duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. 2025.

Cita MLA

Falchi, Lorenzo, et al. Fixed-duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. 2025.